Compounded medications are not FDA approved. FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed.
Compounded GLP-1 Guidepricing database · evidence ledger

Research journal · Tirzepatide

STEP-UP — semaglutide 7.2 mg, the high-dose trial behind Wegovy HD

Design: randomized trial of semaglutide 7.2 mg weekly vs 2.4 mg and placebo in adults with obesity. Topline: ~20.7% average body-weight reduction at the 7.2 mg dose — the basis for the March 19, 2026 Wegovy HD approval — versus the mid-teens at 2.4 mg; GI-dominant adverse events, with altered skin sensation reported more at the top dose and reflected in labeling.

Reading qualifiers: not a head-to-head against tirzepatide — the ~20.7% figure invites comparison with SURMOUNT-5's ~20.2%, but cross-trial comparison is not evidence; populations and designs differ. Dose escalation to 7.2 mg extends the titration runway, and top-dose tolerability governs real-world use.

Relevance to compounded buyers: the HD tier ($399 self-pay) resets the brand ceiling the compounded field is benchmarked against, and features in the pill-vs-injection comparison and the head-to-head explainer. Status: summary pending named-reviewer sign-off; this page remains noindexed until then.